Loading...

Everest Medicines Limited

1952.HK•HKSE
Healthcare
Biotechnology
HK$62.20
HK$5.00(8.74%)

Everest Medicines Limited (1952.HK) Stock Overview

Explore Everest Medicines Limited’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 65.3/100

Key Financials

Market Cap20.2B
P/E Ratio-17.67
EPS (TTM)$-3.54
ROE-0.24%
Fundamental Analysis

AI Price Forecasts

1 Week$48.60
1 Month$46.14
3 Months$58.10
1 Year Target$53.75

1952.HK Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Everest Medicines Limited (1952.HK) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 68.56, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $53.75.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -17.67 and a market capitalization of 20.2B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

68.56RSI (14)
1.15MACD
17.57ADX
Stats data is not available for 1952.HKStats details for 1952.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for 1952.HKAnalyst Recommendations details for 1952.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Everest Medicines Limited, a biopharmaceutical company, engages in discovery, licensing, clinical development, and commercialization of therapies to address critical unmet medical needs in Greater China and other Asia Pacific markets. Its pipeline products include eleven clinical-stage drug candidates for the treatment of oncology, immunology, cardio-renal, and infectious diseases. Everest Medicines Limited was incorporated in 2017 and is headquartered in Shanghai, China.

CEO

Yongqing Luo

Employees

665

Headquarters

Plaza 66, Shanghai

Founded

2020

Frequently Asked Questions

;